AI Article Synopsis
- The study aimed to investigate the effectiveness and safety of Yangxinshi tablets compared to trimetazidine in enhancing exercise tolerance for coronary heart disease (CHD) patients who had undergone percutaneous coronary intervention (PCI).
- A total of 681 patients were enrolled in a randomized trial, with results showing similar improvements in exercise capacity between the Yangxinshi and trimetazidine groups after 24 weeks, indicating non-inferiority of Yangxinshi.
- Additionally, patients taking Yangxinshi reported significantly greater reductions in depression and anxiety symptoms than those taking trimetazidine, with adverse events being comparable in both groups.
Article Abstract
Background: Optimizing medication to improve exercise tolerance in patients with coronary heart disease (CHD) after percutaneous coronary intervention (PCI) is limited. Yangxinshi tablets, an herbal-based oral medicine, relieve symptoms of angina might be that they can improve energy metabolism of the ischemic myocardium. We conducted a randomized trial to assess the efficacy and safety of Yangxinshi vs. trimetazidine in improving exercise tolerance in patients with CHD after PCI.
Methods: This prospective, randomized, double-blind, double-dummy, multicenter, non-inferiority study enrolled patients aged 18-75 years with CHD who underwent their first PCI within 2 months of diagnosis. Patients were randomized to Yangxinshi plus trimetazidine-placebo or trimetazidine plus Yangxinshi-placebo for 24 weeks. The primary endpoint was the change in metabolic equivalents (METs) assessed by cardiopulmonary exercise test (CPET) between 0 and 24 weeks. Secondary endpoints were comprehensive variables of the CPET, health status and adverse events. This study has been registered at ClinicalTrials. gov (NCT03809273).
Results: Between August 1, 2019, and March 31, 2022, a total of 681 patients were randomized to Yangxinshi (n = 341) or trimetazidine (n = 340). After 24 weeks, the exercise tolerance of patients increased by 0.77±1.25 METs in the Yangxinshi group and 0.76±1.00 METs in the trimetazidine group (difference, 0.01; 95 % confidence interval [CI], -0.17 to 0.19), meeting the predefined non-inferiority threshold. Better outcomes were observed in the Yangxinshi group compared with the trimetazidine group for patient-reported depression (PHQ-9; -1.88±3.32 vs. -0.93±3.68; p < 0.001) and anxiety (GAD-7; -1.70±3.26 vs. -0.39±3.29; p < 0.001). Adverse events were similar in both groups.
Conclusions: In patients with CHD after PCI, Yangxinshi was non-inferior to trimetazidine in improving exercise tolerance during the 24-week treatment period. Notably, patients in the Yangxinshi group showed a better mental health profile compared with trimetazidine recipients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.phymed.2024.156198 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Does the modified shuttle test exhibit a ceiling effect in healthy and cystic fibrosis children and adolescents?
Arch Physiother
December 2024
Department of Physiotherapy, Faculty of Medicine and Health Sciences, Universitat Internacional de Catalunya (UIC), Barcelona - Spain.
Introduction: The modified shuttle test-15 (MST-15) is a valid alternative for assessing exercise capacity when a cardiopulmonary exercise testing is not feasible. This study aims to describe the percentage of healthy and cystic fibrosis (CF) children and adolescents reaching the MST-15 ceiling. Additionally, it examines associations between MST-15 distance and demographic, anthropometric, and lung function data.
View Article and Find Full Text PDFAssociations of cognitive decline with outcomes of cardiovascular rehabilitation in patients with cardiovascular disease.
J Cardiol
December 2024
Department of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Japan.
Background: Patients with cardiovascular disease (CVD) are often contending with various comorbidities including cognitive decline. Cognitive decline is a risk marker for adverse outcomes in these patients. On the other hand, cardiovascular rehabilitation (CVR) improves clinical outcomes.
View Article and Find Full Text PDFL-Arginine supplementation as mitochondrial therapy in diabetic cardiomyopathy.
Cardiovasc Diabetol
December 2024
Department of Advanced Biomedical Sciences, Federico II University, Naples, Italy.
In patients with type II diabetes, the development of diabetic cardiomyopathy (DC) is associated with a high risk of mortality. Left ventricular hypertrophy, diastolic dysfunction, and exercise intolerance are the first signs of DC. The underlying mechanisms are not fully elucidated, and there is an urgent need for specific biomarkers and molecular targets for early diagnosis and treatment.
View Article and Find Full Text PDFOne minute of light-intensity stair-stepping decreases postprandial glycaemia in the evening in non-diabetic adults: A randomized controlled trial.
Exp Physiol
December 2024
School of Exercise and Nutritional Sciences, San Diego State University, San Diego, CA, USA.
Prior studies have investigated the efficacy of a single 1 min bout of stair-stepping on reducing postprandial blood glucose (BG) in the morning, but none have investigated this effect in the evening when glycaemic responses are larger due to circadian regulation and β-cell responsiveness. This work investigated the efficacy of a 1 min bout of self-selected, low-intensity stair-stepping performed in the evening on reducing the change from baseline to the 60 min time point postprandial BG. Thirty people (43% male, 29 (10) years) participated in a randomized crossover-controlled trial.
View Article and Find Full Text PDFPost-Acute Sequelae of SARS-CoV-2 Infections: Exercise Limitation and Rehabilitation.
Yale J Biol Med
December 2024
Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas, USA.
Patients with prior SARS-CoV-2 infections can develop chronic symptoms; this clinical presentation has been called post-acute sequelae of SARS-CoV-2 infection, post-COVID condition, and long COVID. It can develop in both outpatient cases and in hospital cases; the frequency depends on the severity of infection and comorbidity. Many of these patients have exercise limitation when tested using cardiopulmonary exercise tests.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!